|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 |
网站主页 >> 化工产品目录 >> 普拉替尼>> 市场分析报告 |
普拉替尼市场分析报告 |
|
Global RET Inhibitors Drug Market Opportunity & Clinical Trials Insight 2026 Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location. 'Global RET Inhibitors Drug Market Opportunity & Clinical Trials Insight 2026' Report Highlights: Global RET Inhibitors Market Opportunity: > USD ... Medullary Thyroid Cancer - Pipeline Review, 2019 ... GI-6207 Ofranergene obadenovec Sapanisertib Vemurafenib Pralsetinib Crolibulin Selpercatinib Debio 1124 Drug ... RET (Ret Proto-Oncogene) protein Inhibitor - Pipeline Insight, 2022 ... Key Products BOS 172738 Sitravatinib Pralsetinib VRN-06 GB 102 Global Oncology Market Outlook to 2027 ... drugs for lung cancer patients (pralsetinib, lurbinectedin, selpercatinib, lapatinib). Besides, FDA ... Next- Generation Sequencing - Market Insight, Competitive Landscape and Market Forecast - 2027 ... who are candidates for GAVRETO™ (pralsetinib), a targeted therapy developed by Blueprint Medicines ... Medullary Thyroid Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 The 7 major medullary thyroid cancer markets reached a value of US$ 141.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 405.1 Million by 2034, exhibiting a growth rate (CAGR) of 10.06% during 2024-2034. The medullary thyroid ... Thyroid Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 The 7 major thyroid cancer markets reached a value of US$ 303.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,624.3 Million by 2034, exhibiting a growth rate (CAGR) of 16.49% during 2024-2034. The thyroid cancer market has ... Global RET Inhibitors Market Research Report 2024(Status and Outlook) ... . Innovnent Biologics Market Segmentation (by Type) Pralsetinib Selpercatinib Market Segmentation (by Application) Non ... |